Xeris Biopharma Holdings (XERS) Other Non Operating Income (2020 - 2026)

Xeris Biopharma Holdings (XERS) has reported Other Non Operating Income for 7 consecutive years, with -$36.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Other Non Operating Income fell 465.9% year-over-year to -$36.3 million; the trailing twelve-month figure through Jun 2026 stood at -$53.8 million (down 110.81% YoY), and the FY2025 full-year result was -$24.3 million, down 3.77% from the prior year.
• Other Non Operating Income declined to -$36.3 million in Q2 2026 per XERS's latest filing, from -$5.7 million in the prior quarter.
• Across five years, Other Non Operating Income topped out at $1.9 million in Q4 2022 and bottomed at -$36.3 million in Q2 2026.
• Historically, Other Non Operating Income has averaged -$6.8 million across 5 years, with a median of -$5.9 million in 2024.
• The sharpest annual moves came in 2022 and 2026: Other Non Operating Income surged 175.51% in 2022, then plunged 465.9% in 2026.
• Over 5 years, Other Non Operating Income stood at $1.9 million in 2022, then plunged by 247.21% to -$2.8 million in 2023, then slumped by 142.57% to -$6.8 million in 2024, then advanced by 16.2% to -$5.7 million in 2025, then tumbled by 537.28% to -$36.3 million in 2026.
• According to Business Quant data, Other Non Operating Income over the past three periods registered -$36.3 million, -$5.7 million, and -$5.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.